Core Viewpoint - Haohai Biological Technology (06826) announced plans to acquire approximately 19.8% and 2.4554% stakes in Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for approximately 38.35 million yuan and 4.756 million yuan respectively, aiming to enter the high-value medical device market in China [1] Group 1 - The target company's products are primarily used in orthopedics and ophthalmology, addressing tendon injury repair, ocular surface burns, wound and injury lesion repair, and tear duct obstruction [1] - By investing in the target company and obtaining distribution rights for its products in China, the company aims to enhance its product portfolio and expand its business layout in the orthopedic and ophthalmic fields [1] - The amniotic materials held by the target company possess human-derived biological characteristics, providing the company with critical technology and material foundations in the fields of regenerative medicine and tissue engineering, which is expected to drive subsequent product innovation and technological upgrades [1]
昊海生物科技拟收购江西瑞济生物工程技术股份有限公司约19.8%股权